How should respiratory fibrosis that develops after durvalumab therapy be managed?

Management of Respiratory Fibrosis Post-Durvalumab

Immediately discontinue durvalumab and initiate high-dose corticosteroids (prednisone 1-2 mg/kg/day or methylprednisolone IV 1-2 mg/kg/day for severe cases) as first-line treatment for immune-related pneumonitis that progresses to fibrosis. 1, 2

Initial Recognition and Grading

When respiratory fibrosis develops after durvalumab, you must first distinguish between immune-related pneumonitis (IrP) with fibrotic evolution versus progressive disease. Key diagnostic features include:

• New or worsening dyspnea within weeks to months of durvalumab exposure
• CT imaging showing ground-glass opacities that may evolve into reticular patterns, traction bronchiectasis, or frank fibrosis
• Exclusion of infection, pulmonary embolism, and tumor progression through appropriate workup (cultures, COVID testing, CT with contrast) 1

The FDA label explicitly warns that pneumonitis occurred in 38.2% of durvalumab-treated patients versus 30.2% on placebo, with immune-related adverse events in 32.1% 2. This is a known, serious toxicity requiring immediate action.

Treatment Algorithm by Severity

Grade 1-2 (Mild to Moderate)

• Hold durvalumab immediately
• Prednisone 1-2 mg/kg/day orally 1
• Monitor weekly with pulse oximetry, clinical assessment
• Consider bronchoscopy with BAL if diagnosis uncertain
• Taper corticosteroids over 4-6 weeks if improvement occurs
• Do not resume durvalumab if fibrotic changes are present

Grade 3-4 (Severe or Life-Threatening)

• Permanently discontinue durvalumab 1, 2
• Methylprednisolone IV 1-2 mg/kg/day 1
• If no improvement after 48-72 hours, add second-line immunosuppression:
  • Infliximab, OR
  • Mycophenolate mofetil IV, OR
  • IVIG, OR
  • Cyclophosphamide 1
• Pulmonary and infectious disease consultation mandatory
• Taper corticosteroids over 4-6 weeks minimum

Critical Pitfall: Steroid-Refractory Fibrotic Progression

The most challenging scenario is when fibrosis predominates and progresses despite corticosteroids. 3 In this situation:

1. Escalate to IV methylprednisolone pulses if not already done
2. Consider adding antifibrotic therapy with nintedanib or pirfenidone - while not FDA-approved for this indication, case reports suggest potential benefit in steroid-refractory cases 3, 4, 5
3. Monitor closely for clinical deterioration - some patients develop progressive fibrotic lung disease despite all interventions

The 2022 ATS/ERS guidelines define progressive pulmonary fibrosis as requiring at least 2 of 3 criteria within one year: worsening symptoms, FVC decline >5% predicted, or radiological progression with increased traction bronchiectasis, new reticulation, or honeycombing 6. This framework helps objectively document progression.

Monitoring and Long-Term Management

Serial pulmonary function testing every 4-6 weeks initially, then every 3-6 months:

• FVC decline >10% or >200 mL indicates significant progression 7
• DLCO decline >15% or >3 mL/min/mm Hg is concerning 7
• Oxygen saturation assessment at rest and with exertion 7

HRCT imaging should be repeated:

• At 3-4 weeks if Grade 1 to assess for progression 1
• More frequently if clinical deterioration occurs
• To distinguish fibrotic evolution from acute inflammatory changes

Supportive Care Essentials

While treating the fibrosis, implement:

• Long-term oxygen therapy if PaO2 <55 mmHg or oxygen saturation <88% 8
• Pulmonary rehabilitation for exercise capacity and quality of life 8
• Influenza and pneumococcal vaccination 8
• Early palliative care consultation for symptom management (dyspnea, cough, anxiety) 7

Lung Transplantation Consideration

Evaluate for lung transplantation early if the patient is <65 years old and develops:

• Severe or rapidly progressive fibrosis
• FVC <50% predicted or DLCO <35% predicted
• Significant functional impairment despite treatment 8

The French guidelines recommend early assessment in transplant centers rather than waiting for end-stage disease 8.

Key Clinical Caveats

Do not restart durvalumab once fibrotic changes are established - the risk of further progression outweighs any oncologic benefit 1, 2. The FDA label states permanent discontinuation is required for Grade 3-4 pneumonitis 2.

Distinguish from radiation pneumonitis if the patient received prior chemoradiotherapy - this can be challenging as both may coexist. Fibrotic changes extending beyond the radiation field suggest immune-mediated disease 3, 9, 10.

Chronic pneumonitis requiring prolonged steroid tapers occurs in <2% of cases but is a recognized phenomenon 1. Some patients require maintenance low-dose corticosteroids for months.

Antifibrotic agents (nintedanib, pirfenidone) are not FDA-approved for immune-related fibrosis but represent a rational approach when standard immunosuppression fails, based on their established efficacy in idiopathic pulmonary fibrosis 3, 4, 5. This is off-label use requiring informed consent and careful monitoring.